Study summary
Starving tumors of arginine added 1.6 months of life
+1.6 momedian survival gain: 9.3 vs 7.7 months
What was tested
Pegargiminase, an enzyme that removes arginine from the blood, with chemotherapy, against placebo with chemotherapy, in non-epithelioid pleural mesothelioma, the harder-to-treat types.
What they found
- Median survival was 9.3 months vs 7.7 months.
- Risk of death was 29% lower.
What it means
A modest gain in the subtypes with the fewest options.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.